These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 6144121)

  • 21. [Chronic treatment of schizophrenia with injectable bromperidol decanoate].
    Suárez Richards M
    Acta Psiquiatr Psicol Am Lat; 1985 Sep; 31(3):222-8. PubMed ID: 2870608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 24. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
    Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
    Leff JP; Tress KH
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychomotor performance of schizophrenic patients and long-term neuroleptic therapy].
    Burr W; Kaiser E
    Psychiatr Clin (Basel); 1983; 16(5-6):316-23. PubMed ID: 6139845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
    Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
    Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 36. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
    Möller HJ; Scharl W; von Zerssen D
    Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Indications for long-term neuroleptic medication--standard procedure or individual prognosis-guided intervention? A prospective study of the clinical treatment model].
    Gaebel W; Pietzcker A
    Nervenarzt; 1983 Sep; 54(9):467-76. PubMed ID: 6138719
    [No Abstract]   [Full Text] [Related]  

  • 39. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.